Prof. Stephen Harrison (USA) discusses state of the art management of non-alcoholic steatohepatitis (NASH) in 2022. He focuses on the benefits of lifestyle recommendations, including nutrition and exercise. He shows that weight loss is associated with NASH resolution and fibrosis regression over time following bariatric surgery in patients with severe obesity and NASH. He mentions that NASH progression to clinical outcomes may take time, hence trials for NASH treatment look at surrogate outcomes (histologic endpoints) which are NASH resolution and/or fibrosis improvement approved by the FDA. Further he explores if NASH is reversible and also looks into the potential targets for NASH treatment.